In a move that has sparked controversy, a committee organized by the Food and Drug Administration (FDA) has voted to endorse removing restrictions on the manufacture of peptides for human use. The decision comes despite a continuing lack of evidence regarding their safety and effectiveness.
The vote was widely expected, given the influence of Health and Human Services Secretary Robert F. Kennedy Jr., who is known for his enthusiasm for peptide supplements. Kennedy had taken steps to ensure this outcome by adding members to the advisory group with obvious interests in the manufacture and sale of unapproved peptides. These new members provided the decisive votes for overturning the ban, with all pre-Kennedy members voting against doing so.
The move has raised concerns about the safety of these peptide supplements, which are often used without rigorous scientific evaluation. While some peptides have been approved by the FDA through standard processes, many others remain untested and unregulated. The lack of evidence on their safety and efficacy is a critical factor in this decision, as it may put consumers at risk.
The committee’s role is advisory, and the FDA could reject its recommendations. However, doing so would place the agency’s experts in direct conflict with Kennedy’s wishes, who can simply fire them. This raises questions about the independence of the FDA and its ability to regulate the industry effectively.
Peptides are short chains of amino acids that differ from proteins by length. They are often used as supplements due to their potential benefits for various health conditions. However, understanding how a peptide is made and what downstream effects it triggers can take decades of research. In many cases, we have some evidence of what happens when we expose cultured cells to a peptide, but lack any indication of what might happen if an intact animal is exposed.
The FDA has already used its standard processes to approve peptide drugs like insulin and some recently developed weight loss drugs. However, the lack of safety and efficacy data has kept most peptides off the market. The Biden administration also blocked their manufacture by compounding pharmacies, which make specialty drugs. But Kennedy’s announcement earlier this year to reverse that ban sparked concerns about his influence on the industry.
In June, Kennedy added members to the advisory group who had obvious interests in the manufacture and sale of unapproved peptides. Yesterday, those newly appointed members provided the decisive votes for overturning the ban, with all pre-Kennedy members voting against doing so. Despite Kennedy’s earlier claim that ‘independent experts will rigorously evaluate each substance on its scientific merits using full clinical, pharmacological, and safety evidence,’ no such evidence was presented at the meeting.
The FDA official noted that it had not approved anything that had never been tested in humans before. This may be a critical factor in what happens next. The committee’s recommendations are advisory, and the FDA could reject them. However, doing so would place the agency’s experts in direct conflict with Kennedy’s wishes, who can simply fire them.
Source: Original article